NASDAQ
SYBX

Synlogic Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Synlogic Inc Stock Price

Vitals

Today's Low:
$0.3401
Today's High:
$0.376
Open Price:
$0.37
52W Low:
$0.3401
52W High:
$1.35
Prev. Close:
$0.364
Volume:
313201

Company Statistics

Market Cap.:
$24.94 million
Book Value:
0.798
Revenue TTM:
$993000
Operating Margin TTM:
-6801.01%
Gross Profit TTM:
$1.18 million
Profit Margin:
0%
Return on Assets TTM:
-37.88%
Return on Equity TTM:
-75.85%

Company Profile

Synlogic Inc had its IPO on 2015-10-01 under the ticker symbol SYBX.

The company operates in the Healthcare sector and Biotechnology industry. Synlogic Inc has a staff strength of 72 employees.

Stock update

Shares of Synlogic Inc opened at $0.37 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.34 - $0.38, and closed at $0.34.

This is a -6.54% slip from the previous day's closing price.

A total volume of 313,201 shares were traded at the close of the day’s session.

In the last one week, shares of Synlogic Inc have slipped by -27.77%.

Synlogic Inc's Key Ratios

Synlogic Inc has a market cap of $24.94 million, indicating a price to book ratio of 0.4911 and a price to sales ratio of 31.1668.

In the last 12-months Synlogic Inc’s revenue was $993000 with a gross profit of $1.18 million and an EBITDA of $-65165000. The EBITDA ratio measures Synlogic Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Synlogic Inc’s operating margin was -6801.01% while its return on assets stood at -37.88% with a return of equity of -75.85%.

In Q2, Synlogic Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 77%.

Synlogic Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.94 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Synlogic Inc’s profitability.

Synlogic Inc stock is trading at a EV to sales ratio of 7.7403 and a EV to EBITDA ratio of 0.3545. Its price to sales ratio in the trailing 12-months stood at 31.1668.

Synlogic Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$79.28 million
Total Liabilities
$9.63 million
Operating Cash Flow
$0
Capital Expenditure
$43000
Dividend Payout Ratio
0%

Synlogic Inc ended 2024 with $79.28 million in total assets and $0 in total liabilities. Its intangible assets were valued at $79.28 million while shareholder equity stood at $54.77 million.

Synlogic Inc ended 2024 with $0 in deferred long-term liabilities, $9.63 million in other current liabilities, 73000.00 in common stock, $-387689000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $46.26 million and cash and short-term investments were $46.26 million. The company’s total short-term debt was $4,350,000 while long-term debt stood at $0.

Synlogic Inc’s total current assets stands at $49.56 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0 compared to accounts payable of $1.08 million and inventory worth $0.

In 2024, Synlogic Inc's operating cash flow was $0 while its capital expenditure stood at $43000.

Comparatively, Synlogic Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.34
52-Week High
$1.35
52-Week Low
$0.3401
Analyst Target Price
$5

Synlogic Inc stock is currently trading at $0.34 per share. It touched a 52-week high of $1.35 and a 52-week low of $1.35. Analysts tracking the stock have a 12-month average target price of $5.

Its 50-day moving average was $0.49 and 200-day moving average was $0.63 The short ratio stood at 2.37 indicating a short percent outstanding of 0%.

Around 1636.2% of the company’s stock are held by insiders while 5089.9% are held by institutions.

Frequently Asked Questions About Synlogic Inc

The stock symbol (also called stock or share ticker) of Synlogic Inc is SYBX

The IPO of Synlogic Inc took place on 2015-10-01

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
Canopy Finance Ltd (CANOPYFIN)
$58.89
0.88
+1.52%
Cupid Limited (530843)
$390.1
-36.35
-8.52%
$24.66
0.73
+3.05%
$380.2
0.3
+0.08%
$1.72
-0.11
-6.01%
$3.35
-0.15
-4.29%
$2.01
-0.04
-1.95%
$29.29
0.1
+0.34%
$5.65
-0.29
-4.88%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Address

301 Binney Street, Cambridge, MA, United States, 02142